A Phase 2 interventional study of Decitabine in Acute Myelogenous Leukemia and Myelodysplastic Syndrome, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-08.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.
Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 103rd largest by enrollment of the 120 interventional ones that give a count, is one of 4 that started in 2005, is one of 53 in phase 2, and was the 13th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Portugal, Spain
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages up to 21
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
David Avigan · Sites in United States
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 72 · Phase 3 13 · Phase 4 2
First in 1995; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 32 across the 120 interventional studies. Of the 67 that completed or were terminated, 39 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 121 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 6 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
6 of the studies testing decitabine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06129734Benjamin TomlinsonDecitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | 2027-03 |
| NCT05190471Bio-Path Holdings, Inc.A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | 2027-03 |
| NCT05222984City of Hope Medical CenterNavitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | 2027-03-02 |
| NCT07012044National Cancer Institute (NCI)A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia | 2027-03-31 |
| NCT07374029David AviganAdoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide decitabine to patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who have completed participation per protocol in the DACO-018 study.
The objectives of this trial are:
The purpose of this open-label, expanded-access trial is to provide decitabine to patients with AML or MDS who have completed participation per protocol in the DACO-018 study and for whom continuation of treatment with decitabine is indicated, per the opinion of the investigator. In order to continue treatment with decitabine, at a minimum, there must be no disease progression while the patient was participating in the DACO-018 trial and during the period after the patient discontinued from the DACO-018 study and before entering this trial. Patients must enroll in this trial within 8 weeks of discontinuing from the DACO-018 study and not have received any other chemotherapy for their disease during this interim period.
Decitabine will be administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have had one of the following:
MDS (de novo or secondary) fitting any of the recognized French-American-British classifications
OR
chronic myelomonocytic leukemia (with WBC \<12,000/μL)
AND
an International Prognostic Scoring System score of ≥1.5 as determined by complete blood count, bone marrow assessment and bone marrow cytogenetics within 30 days of study entry OR AML (≥ 30 % bone marrow blasts), except M3 or acute promyelocytic leukemia.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Decitabine will be administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks.
Drug: Decitabine
Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
Also known as: Dacogen
The Number of Subjects With Adverse Events
Generate safety information when patients were also taking concomitant medications and/or therapies without trial restrictions when decitabine was administered at a dose of 20 milligrams per meter squared (mg/m\^2) over a 1-hour intravenous (IV) infusion for 5 consecutive days every 4 weeks in patients with MDS (\< 30% blasts) or AML (\> 30% blasts).
Time frame: 3 months
| Milestone | Decitabine |
|---|---|
| Started | 10 |
| Completed | 0 |
| Not completed | 10 |
| Withdrew: Physician decision | 5 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Progressive disease | 3 |
Generate safety information when patients were also taking concomitant medications and/or therapies without trial restrictions when decitabine was administered at a dose of 20 milligrams per meter squared (mg/m\^2) over a 1-hour intravenous (IV) infusion for 5 consecutive days every 4 weeks in patients with MDS (\< 30% blasts) or AML (\> 30% blasts).
| participants | Decitabine |
|---|---|
| The Number of Subjects With Adverse Events | 10 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Decitabine | — | 6/10 (60%) | 10/10 (100%) |
| Event | Decitabine |
|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/10 |
| NeutropeniaBlood and lymphatic system disorders | 1/10 |
| Cardiac Failure CongestiveCardiac disorders | 1/10 |
| Cellulitis GangrenousInfections and infestations | 1/10 |
| Clostridium Difficile ColitisInfections and infestations | 1/10 |
| Pneumonia Primary AtypicalInfections and infestations | 1/10 |
| Pseudomonal BacteremiaInfections and infestations | 1/10 |
| Lung AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/10 |
| Hemorrhage IntracranialNervous system disorders | 1/10 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/10 |
| Event | Decitabine |
|---|---|
| FatigueGeneral disorders | 8/10 |
| NauseaGastrointestinal disorders | 4/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/10 |
| ConstipationGastrointestinal disorders | 3/10 |
| DiarrhoeaGastrointestinal disorders | 3/10 |
| PyrexiaGeneral disorders | 3/10 |
| Back PainMusculoskeletal and connective tissue disorders | 3/10 |
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 3/10 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/10 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/10 |
| Age Continuous(years) | Decitabine |
|---|---|
| Mean | 68.5 ± 11.15 |
| Sex: Female, Male(Participants) | Decitabine |
|---|---|
| Female | 2 |
| Male | 8 |
| Race (NIH/OMB)(Participants) | Decitabine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 8 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Decitabine |
|---|---|
| United States | 10 |
The record gives a start of Jul 2005, a primary completion of Sep 2005 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 5 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Decitabine